OTIS Q1 2026 Earnings EPS Misses Estimates by 185 as Market Digests Mixed Signals CRVO Q1 2026 Earnings EPS Miss Reflects Continued Clinical Investment PYPD Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Pipeline Advances YSG Q4 2025 Earnings Positive EPS but Revenue Transparency Remains Limited Sarepta Therapeutics Q1 2026 Earnings Robust EPS Beat Amid Modest Market Caution ACRE Q1 2026 Earnings Deeper Than Expected Loss Despite Positive Stock Reaction